Related by context. All words. (Click for frequent words.) 78 F FDG PET 74 FDG-PET/CT 73 #F FDG PET 70 #F FDG 70 lymph node metastases 69 EUS FNA 68 KRAS mutation 68 immunohistochemical staining 68 myocardial viability 68 FDG uptake 68 PET imaging 68 conventional angiography 67 neoadjuvant chemotherapy 67 fluorodeoxyglucose positron emission tomography 67 lymphadenectomy 67 FDG PET imaging 67 pelvic lymphadenectomy 66 pCR 66 PSADT 66 immunohistochemical analysis 66 FDG PET CT 66 prostate cancer CaP 66 immunohistochemical 66 myocardial perfusion 66 biochemical recurrence 66 urine cytology 66 preoperative staging 66 bone scintigraphy 65 scintigraphic 65 distant metastasis 65 adjuvant therapies 65 subgroup analyzes 65 CT angiography 65 sentinel lymph node biopsy 65 histopathological 65 mediastinoscopy 65 prognostic indicator 65 perfusion imaging 65 adjuvant chemotherapy 65 COR Analyzer 65 coronary CT angiography 65 neoadjuvant 65 urothelial carcinoma 65 catheter angiography 65 chest radiographs 65 neoadjuvant therapy 65 adjuvant radiotherapy 65 prognostic variables 65 endosonography 65 malignant lesions 65 Computed tomography 65 prognostic marker 64 scintigraphy 64 nodal metastases 64 EBUS FNA 64 chemoradiotherapy 64 Kaplan Meier analysis 64 lymph node metastasis 64 renal tumors 64 nodal metastasis 64 angiography CCTA 64 duplex ultrasonography 64 prognostic 64 DCE MRI 64 Subgroup analysis 64 Computed tomographic 64 TRUS 64 MR imaging 64 flurpiridaz F 64 transient elastography 64 fluorodeoxyglucose 64 sonographic findings 64 spiral computed tomography 64 neoadjuvant treatment 64 colonography 64 preoperative chemotherapy 64 conventional coronary angiography 64 Lymph node 64 positron emission 64 micrometastasis 64 prognostic significance 64 histopathologic 64 Randomized trials 64 coronary angiography 64 breast carcinoma 64 HER2 expression 64 prostate carcinoma 64 prognostic markers 64 clinically localized prostate 63 curative resection 63 sensitivity specificity 63 radical nephrectomy 63 nodal dissection 63 PCa 63 Subgroup analyzes 63 transvaginal sonography 63 CT colonography 63 SLNB 63 clinicopathological features 63 lymphovascular invasion 63 PROLARIS 63 imaging modality 63 MR spectroscopy 63 adjuvant therapy 63 multivariate Cox 63 SPECT CT imaging 63 invasive coronary angiography 63 pT2 63 SUVmax 63 occult metastases 63 lymph node involvement 63 gadolinium enhanced 63 fine needle aspiration 63 prognostic indicators 63 liver metastasis 63 excisional biopsy 63 risk stratification 63 transurethral resection 63 Preoperative 63 PET CT 63 thyroglobulin 63 SPECT 63 prognostic biomarker 63 HERmark 63 precursor lesions 63 cytoreductive nephrectomy 63 predictive biomarker 63 thyroid nodules 63 fluorodeoxyglucose FDG 63 Sentinel Lymph Node Biopsy 63 coronary computed tomography 63 RECIST Response Evaluation Criteria 62 cytoreductive surgery 62 prostate cancer PCa 62 troponins 62 differentiated thyroid 62 CIN2 + 62 stratifying patients 62 #F FDG PET CT 62 optical colonoscopy 62 Radical prostatectomy 62 Randomized clinical trials 62 multivariable analysis 62 oncologic outcomes 62 PET scanning 62 Immunohistochemistry 62 F FDG uptake 62 transesophageal echocardiography 62 digital subtraction angiography 62 micrometastases 62 NMIBC 62 Response Evaluation Criteria 62 SLN biopsy 62 CT Colonography 62 ultrasonographic 62 perfusion abnormalities 62 Coronary CTA 62 electron beam computed tomography 62 histologic 62 liver biopsy 62 axillary dissection 62 PET CT scans 62 preoperative diagnosis 62 pulmonary nodules 62 CT perfusion 62 myocardial perfusion imaging 62 K ras mutations 62 endoscopic ultrasonography 62 medically inoperable 62 ^ sup #m 62 KRAS mutations 62 cytologic 62 cardiac perfusion 62 Screening Trial DMIST 62 Ultrasonography 62 MDCT 62 pretargeting 62 transrectal ultrasound guided 62 multivariate analyzes 62 Angiographic 62 advanced neoplasia 62 RE LY trial 62 resectable 62 glomerular filtration 62 florbetaben 62 distant metastases 62 MSCT 62 pulmonary angiography 62 chemoradiation therapy 62 TRUS biopsy 62 debulking surgery 62 prospectively defined 61 tumor resection 61 PET CT colonography 61 cardiac computed tomography 61 CT Angiography 61 KRAS status 61 prognostic factor 61 arteriography 61 ischemic lesions 61 helical CT 61 HER2 overexpression 61 Tumor Response 61 Multivariate logistic regression 61 radical prostatectomy RP 61 computed tomographic 61 radical cystectomy 61 cystectomy 61 prophylactic cranial irradiation 61 liposomal amphotericin B 61 extracolonic findings 61 biodistribution 61 multidetector row 61 Histologic 61 echocardiographic 61 STRIDE PD 61 antiangiogenic therapy 61 Sentinel node biopsy 61 lymph node dissection 61 radiotracer 61 tumor recurrence 61 F FDG 61 Doxil ® 61 tumor histology 61 percutaneous biopsy 61 PSA nadir 61 transcranial Doppler 61 gene amplification 61 EpCAM 61 locoregional 61 pulmonary metastases 61 biomarker 61 hepatocellular carcinoma 61 BSGI 61 transabdominal 61 EGFR mutations 61 mucinous 61 Multiple logistic regression 61 advanced adenomas 61 chemoembolization 61 Prostate specific antigen 61 adjuvant radiation 61 CT angiogram 61 intravesical therapy 61 Prognostic Value 61 sentinel lymph nodes 61 specific antigen PSA 61 histopathologic diagnosis 61 sentinel node biopsy 61 liver resection 61 logistic regression analysis 61 pharmacodynamic PD 61 proton MR spectroscopy 61 cTnI 61 HSCT 61 ImmuKnow assay 61 colonoscopic 61 microvessel density 61 serum PSA 61 PITX2 methylation 61 biopsied tissue 61 hsCRP 61 mediastinal lymph nodes 61 D dimer 61 nephron sparing surgery 61 prognostic factors 61 colorectal liver metastases 61 metastatic RCC 61 MTWA testing 61 contralateral breast 61 Ejection Fraction 61 metastatic lesions 61 unresectable tumors 61 plain radiographs 61 FDG PET scans 61 axillary lymph nodes 61 postoperative radiotherapy 61 Neoadjuvant 61 Oncotype DX Recurrence Score 61 infarct size 61 pathologic examination 61 viral kinetics 61 ultrasonography 61 histological subtype 60 lung nodules 60 MGd 60 TURBT 60 positron emission tomography scans 60 KRAS mutation status 60 Magnetic resonance 60 arthrography 60 cardiac magnetic resonance 60 locoregional recurrence 60 bleomycin 60 ASCUS 60 antiplatelet therapies 60 CTEPH 60 sentinel lymph node 60 univariate 60 microsatellite instability 60 histopathologic examination 60 central corneal thickness 60 endoscopic ultrasound 60 mammographic density 60 cystoscopy 60 TOP2A 60 intracoronary 60 surrogate marker 60 pancreatic adenocarcinoma 60 Kaplan Meier 60 coronary stenosis 60 ultrasound elastography 60 OPCAB 60 antitumor effect 60 nephrectomy 60 Adjuvant therapy 60 logistic regression analyzes 60 sonographic 60 BMS# 60 Mammographic 60 HGPIN 60 epithelial tumors 60 underwent resection 60 tumor subtypes 60 Elastography 60 iodixanol 60 Metastatic 60 tracer uptake 60 axillary nodes 60 ProstaScint 60 Zevalin consolidation 60 #F fluorodeoxyglucose 60 pharmacodynamic effects 60 DaTscan 60 coronary CTA 60 endometrial carcinoma 60 gefitinib Iressa 60 biochemical relapse 60 morphologic 60 preoperatively 60 postoperative mortality 60 Positron emission tomography 60 biopsy specimens 60 recurrent glioblastoma multiforme 60 histologically 60 gemcitabine Gemzar 60 miRview ™ squamous 60 computed tomographic scans 60 histopathologic findings 60 cystatin C 60 adrenalectomy 60 antiangiogenic agents 60 gene polymorphisms 60 rFVIIa 60 multivariate logistic regression 60 immunostaining 60 chemosensitivity 60 lung metastases 60 symptomatic VTE 60 prospective multicenter study 60 Recurrence Score 60 NGAL 60 multislice CT 60 node metastases 60 preoperative MRI 60 parathyroidectomy 60 coronary artery stenosis 60 postoperative chemotherapy 60 chest radiography 60 antigen PSA levels 60 NSCLC tumors 60 B7 H3 60 differentiate squamous 60 univariate analyzes 60 Coronary artery calcium 60 ALA PDT 60 dimensional echocardiography 60 hepatic resection 60 adenomatous 60 immunohistochemistry IHC 60 GP IIb IIIa inhibitors 60 patients undergoing CABG 60 liver metastases 60 cCTA 60 renal cell carcinomas 60 xenograft models 60 diagnostic modality 60 angiography CTA 60 neurologic progression 60 Logistic regression analysis 60 malignant nodules 60 Poisson regression 60 progesterone receptor PR 60 axillary lymph node 60 tumor biopsies 60 Prognostic 60 Surgical resection 60 immunohistochemistry 60 surrogate endpoint 59 core needle biopsy 59 p# biomarker 59 surrogate markers 59 Immunohistochemical staining 59 XELOX 59 semiquantitative 59 HER2 positive metastatic breast 59 mRCC 59 Echocardiographic 59 transthoracic 59 metastatic lymph nodes 59 ^ Tc 59 external beam radiotherapy 59 castration resistant prostate cancer 59 eplerenone 59 galiximab 59 lung resection 59 HNSCC 59 SYNTAX trial 59 invasive carcinoma 59 Cardiotoxicity 59 axillary node dissection 59 conditional logistic regression 59 pediatric malignancies 59 radiotherapy RT 59 chemoprevention trials 59 baseline LDH 59 posttreatment 59 postoperative morbidity 59 mammographic 59 diffusion tensor 59 sentinel node 59 Adjuvant chemotherapy 59 noncardiac 59 pretest probability 59 HIV HCV coinfected 59 estimated GFR 59 radiation dosimetry 59 SPECT imaging 59 pancreatic lung 59 olaparib 59 underwent surgical resection 59 wedge resection 59 benign lesions 59 mammographically 59 HER2 positive cancers 59 mRNA expression 59 IL#B 59 recurrent GBM 59 LV dysfunction 59 hormone receptor status 59 carotid stenosis 59 NMP# 59 prostate biopsy 59 mediastinal 59 Trofex 59 RQ PCR 59 VEGF expression 59 hepatocellular carcinomas 59 eGFR 59 angiographically 59 biomarkers 59 oral Xeloda 59 concurrent chemoradiation 59 CSF biomarkers 59 T1 weighted images 59 R0 resection 59 androgen deprivation 59 hemodynamic variables 59 Histological 59 BRAF mutation 59 DXA 59 randomized controlled trials RCTs 59 TACE 59 breast cancer subtypes 59 imatinib therapy 59 precancer 59 intact parathyroid hormone 59 immunochemical 59 metabolic parameters 59 histologically proven 59 adenoma recurrence 59 clinico pathological 59 Vectibix monotherapy 59 resected 59 sentinel nodes 59 rosuvastatin #mg 59 tumorigenicity 59 Logistic regression 59 preoperative PSA 59 nomogram 59 hepatic lesions 59 Doppler sonography 59 HRCT 59 intraobserver 59 polyp detection 59 interobserver agreement 59 lymphatic mapping 59 abdominal computed tomography 59 pre operatively 59 adenomatous polyps 59 adnexal mass 59 NPM1 mutation 59 coronary arteriography 59 renal artery stenosis 59 lung metastasis 59 Radiofrequency ablation 59 Annexin V 59 Azedra 59 Papillary 59 noninvasive imaging 59 lung nodule 59 EBRT 59 upper endoscopy 59 nonmetastatic 59 PET CT imaging 59 metastatic neuroendocrine tumors 59 fibrinolytic therapy 59 pigmented skin lesions 59 elevated LDH 59 serum albumin 59 histologic findings 59 cardiac troponin T 59 digital rectal examination 59 platelet reactivity 59 interobserver reliability 59 myocardial necrosis 59 fosbretabulin 59 SABCS 59 Pharmacodynamic 59 Sipuleucel T 59 colorectal neoplasms 59 cervical lymph nodes 59 WT1 59 renal biopsy 59 transgene expression 59 pre malignant lesions 59 PET scans 59 cystoscopic 59 venography 59 miRview mets 59 Breast Specific Gamma 59 endoscopic resection 59 multicenter trials 59 TIMP 59 pathologic diagnosis 59 chemoresistant 59 lactate dehydrogenase LDH 59 pelvic ultrasound 59 SBRT 59 CT coronary angiography 59 biochemical marker 59 multimodality therapy 59 adenoma detection 59 sestamibi 59 FDG PET scan 59 thyroid stimulating hormone 59 ovarian carcinoma 59 lymphadenopathy 59 Thrombolysis 59 hyperintense lesions 59 Epidemiologic studies 58 Lp PLA 2 58 kidney cysts 58 leiomyomas 58 acetabular fractures 58 Breast Specific 58 cardiac troponin 58 Enzastaurin 58 antiangiogenic agent 58 enhanced sonography 58 perioperative mortality 58 sorafenib Nexavar 58 nomograms 58 Positron emission tomography PET 58 advanced adenoma 58 tumor necrosis 58 relapsed SCLC 58 intraperitoneal chemotherapy 58 cranial irradiation 58 detecting polyps 58 pT3 58 colorectal adenoma 58 EBUS 58 adecatumumab 58 coronary angiogram 58 sunitinib Sutent 58 hsCRP levels 58 urine NGAL 58 Prognostic factors 58 flexible sigmoidoscopy 58 5-fluorouracil/leucovorin 58 spirometric 58 PSA kinetics 58 Stereotactic Body Radiation Therapy 58 metastatic lesion 58 molecular biomarkers 58 secretin 58 Immunohistochemical analysis 58 immunoreactivity 58 MR angiography 58 virologic responses 58 ECG gated 58 MitraClip device 58 cytological 58 perioperative morbidity 58 beta blocker therapy 58 Univariate analysis 58 lactate dehydrogenase 58 HoLEP 58 PET CT scanning 58 metastases 58 ELISPOT 58 pharmacodynamic 58 esophageal carcinoma 58 fulvestrant 58 lipid lowering therapy 58 partial nephrectomy 58 adenoma 58 colorectal tumors 58 comorbid conditions 58 F FLT 58 alkaline phosphatase ALP 58 squamous histology 58 liver histology 58 extracolonic 58 urography 58 #m Tc 58 miRview squamous 58 SCr 58 BSGI MBI 58 CANCIDAS 58 PROSTASCINT 58 fetal echocardiography 58 syngeneic 58 sleeve lobectomy 58 logistic regression models 58 endometrial hyperplasia 58 neratinib 58 cediranib 58 seminal vesicle invasion 58 positron emission tomography PET 58 bi ventricular pacing 58 pathologic 58 perioperative complications 58 HCV SPRINT 58 glycoprotein IIb IIIa inhibitors 58 localized renal 58 ImmuKnow 58 PITX2 58 VKORC1 58 radioiodine therapy 58 mCi 58 DEXA scan 58 clinicopathological 58 vivo 58 oral anticoagulation 58 IGF 1R 58 eTag assays 58 temsirolimus 58 antigen PSA 58 diffusion weighted 58 stratify patients 58 androgen suppression 58 atypical hyperplasia 58 nephrotoxicity 58 taxane therapy 58 pancreatic carcinoma 58 plasma pharmacokinetics 58 postoperative complication 58 liver fibrosis 58 chemoradiation 58 DNA methylation markers 58 soluble CD# ligand 58 T2DM 58 Positron Emission Tomography PET 58 peritoneal carcinomatosis 58 extramedullary 58 NCCN guidelines 58 mitomycin C 58 neoplastic cells 58 univariate analysis 58 hepatic metastases 58 hamartomas 58 Prostate Cancer Progression 58 GnRH agonists 58 MDRD equation 58 atypical ductal hyperplasia 58 Ultrasonographic 58 stress echocardiography 58 cerebral perfusion 58 fluorescein angiography 58 Postoperative 58 dosimetric 58 isoprostane 58 multislice 58 liposomal doxorubicin 58 Coronary Artery Bypass Graft 58 BRCA2 mutation carriers 58 Imaging BSGI 58 mycophenolate mofetil 58 liver transplant recipients 58 antiplatelet therapy 58 multivariate regression analysis 58 Hurthle cell 58 myocardial revascularization 58 FOLFOX4 58 enhanced MR angiography 58 genetic polymorphisms 58 magnetic resonance angiography 58 annexin V 58 NovoTTF 58 multivariable logistic regression 58 extracranial 58 ICD therapy 58 secondary efficacy endpoint 58 riociguat 58 HER3 58 radiographic findings 58 RECIST criteria 58 myocardial infarct size 58 thyroid carcinoma 58 PSA velocity 58 carcinoid tumor 58 conventional cytology 58 invasive angiography 58 breast lesions 58 anti JCV antibodies 58 interobserver 58 MAGE A3 58 carotid artery stenting 58 ADAS Cog 58 GISTs 58 MMSE score 58 histological subtypes 58 pertuzumab 58 Bezielle 58 retrospective cohort 58 intima media thickness 58 CT angiograms 58 polypectomy 58 etiologic 58 multidetector CT 58 Bevacizumab 58 CR nPR 58 Estrogen Receptor 58 vorinostat 58 HER2 gene 58 TNM staging 58 EGFR inhibitors 58 lung lesions 58 bioluminescent imaging 58 malignant pleural mesothelioma 58 postprocedure 58 PET tracer 57 malignant lymph nodes 57 GSTP1 57 computed tomography scan 57 PNH patients 57 hepatectomy 57 Adenomas 57 periprocedural MI 57 SCD HeFT 57 Trastuzumab 57 Ki# 57 HORIZONS AMI trial 57 atheroma volume 57 retroperitoneal 57 Photodynamic therapy 57 Endoscopic ultrasound 57 esophagectomy 57 tumor hypoxia 57 vitro experiments 57 radioimmunotherapy RIT 57 stereotactic radiotherapy 57 elective PCI 57 malignant lymphoma 57 PLCO 57 PSMA ADC 57 radiolabeled 57 contrast echocardiography 57 colorectal adenocarcinoma 57 carotid plaque 57 bladder carcinoma 57 EndoTAGTM 1 57 predictive biomarkers 57 trastuzumab Herceptin ® 57 epithelial ovarian cancer 57 orthotopic 57 MR arthrography 57 hepatic arterial 57 Observational studies 57 aminotransferases 57 superficial bladder cancer 57 Digital Mammographic Imaging 57 idraparinux 57 core needle biopsies 57 dimensional sonography 57 glomerular filtration rate 57 PCA3 57 microRNA expression 57 preoperative evaluation 57 relapsed MM 57 Accelerated Partial Breast Irradiation 57 Meta analyzes 57 p# activation 57 MammaPrint R 57 Cystatin C 57 prospectively randomized 57 Biopsies 57 D Dimer 57 hematologic parameters 57 EGFR inhibition 57 substudy 57 MDCT angiography 57 Positron Emission Tomography 57 inotropic 57 nonresponders 57 fibrinolytic 57 erlotinib Tarceva ® 57 potentially cancerous polyps 57 serologic 57 diagnostic workup 57 sonographically guided 57 antioxidant supplementation 57 adenocarcinomas 57 mitomycin 57 gastric adenocarcinoma 57 histologic examination 57 gated SPECT 57 ovarian malignancy 57 esophagogastric 57 histologies 57 stenoses 57 MiCK assay 57 VADT 57 Solid Tumors RECIST 57 TroVax ® 57 Immunohistochemical 57 computed tomography angiography 57 mesothelin 57 antibiotic prophylaxis 57 computerized tomography scans 57 annexin 57 histologically confirmed 57 myocardial ischemia 57 LHRH agonists 57 mutational status 57 prognostically 57 stage IIIB 57 metachronous 57 sarcosine 57 nab paclitaxel 57 cancer mCRC 57 quantitative RT PCR 57 Solid Tumors 57 BEXXAR Therapeutic Regimen 57 Mitomycin C 57 RE LY ® 57 CYP#D# genotype 57 ZOLINZA 57 Virtual Colonoscopy 57 cervical carcinoma 57 hepatic fibrosis 57 PD2i ® 57 Gastrointestinal Stromal Tumors 57 RALP 57 apolipoproteins 57 Pharmacokinetic PK 57 hyperacute 57 endothelin antagonists 57 invasive aspergillosis 57 thrombolytic therapy 57 qRT PCR 57 hypervascular 57 independent prognostic marker 57 T1a 57 fluvastatin 57 promoter methylation 57 ductal adenocarcinoma 57 GAMMAGARD 57 Natalizumab 57 imatinib Gleevec 57 antitumor efficacy 57 NIHSS 57 immunoblotting 57 carotid artery stenosis 57 Kinoid 57 clinicopathologic 57 Coronary Angiography 57 angiographic outcomes 57 pituitary adenomas 57 Histopathologic 57 neurocognitive function 57 oncological outcomes 57 paricalcitol 57 EGFR tyrosine kinase inhibitors 57 transrectal ultrasound 57 clusterin 57 EGFR expression 57 NMP# assay 57 transesophageal 57 single photon emission 57 spontaneous regression 57 Percutaneous Coronary Intervention 57 papillary thyroid carcinoma 57 micafungin 57 meta regression 57 Kaplan Meier method 57 esophagogastroduodenoscopy 57 LV hypertrophy 57 sipuleucel T 57 ICD implantation 57 EGFR mutation status 57 standard chemotherapy regimen 57 percutaneous cryoablation 57 endocrine therapies 57 elevated CRP 57 CYT# potent vascular disrupting 57 concomitant medications 57 malignant polyps 57 antitumour activity 57 CCX# 57 nonfatal MI 57 cisplatin resistant 57 STN stimulation 57 cerebral microbleeds 57 K ras mutation 57 antibody titer 57 HER2 amplification 57 BFPET 57 immunochemical fecal occult 57 antiangiogenic activity 57 MR Angiography 57 genotypic resistance 57 genomic biomarker 57 metastatic malignant 57 progesterone receptor 57 colorectal carcinoma 57 Coronary angiography 57 estrogen receptor ER 57 FGFR4 57 radioligand 57 DCIS lesions 57 multiple logistic regression 57 parenchymal 57 Radiographic 57 SPECT CT 57 NPRL2 57 Abciximab 57 breast carcinomas 57 Doppler imaging 57 radiotherapy SBRT 57 carotid endarterectomy 57 OncotypeDX 57 EGFR mutation 57 T2 weighted images 57 APOPTONE 57 sirolimus eluting stents 57 metaplasia 57 operable breast cancer 57 bone metastasis 57 carotid intima media 57 axillary node 57 logistic regression 57 Degarelix 57 radionuclide imaging 57 Intra operative 57 grade cervical intraepithelial 57 crizotinib PF # 57 Carotid Revascularization Endarterectomy vs. 57 specific antigen 57 PIB PET 57 randomizing patients 57 TIMP 1 57 pharmacologic stress 57 exploratory endpoints 57 CALGB 57 Liver biopsy 57 fibrinolysis 57 MDCTA 57 eosinophil count 57 pharmacodynamic parameters 57 glycated hemoglobin levels 57 TAXUS Liberte Stent 57 albuminuria 57 leflunomide 57 Pertuzumab 57 ToGA 57 HAAH 57 atherothrombotic disease 57 allogeneic hematopoietic stem cell 57 ZACTIMA 57 liver biopsies 57 BRAF mutations 57 genomic alterations 57 axillary lymph node dissection 57 perioperatively 57 carcinoembryonic antigen 57 cTnT